4.08
0.24 (6.25%)
| Penutupan Terdahulu | 3.84 |
| Buka | 3.80 |
| Jumlah Dagangan | 1,251,591 |
| Purata Dagangan (3B) | 675,423 |
| Modal Pasaran | 130,621,608 |
| Harga / Jualan (P/S) | 0.270 |
| Harga / Buku (P/B) | 0.940 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 5 Feb 2025 - 10 Feb 2025 |
| Margin Keuntungan | -19.80% |
| Margin Operasi (TTM) | -17.29% |
| EPS Cair (TTM) | -4.19 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -32.80% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 236.01% |
| Nisbah Semasa (MRQ) | 0.310 |
| Aliran Tunai Operasi (OCF TTM) | 14.33 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 26.63 M |
| Pulangan Atas Aset (ROA TTM) | -2.91% |
| Pulangan Atas Ekuiti (ROE TTM) | -43.15% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Diagnostics & Research (US) | Bercampur | Bercampur |
| Diagnostics & Research (Global) | Bercampur | Bercampur | |
| Stok | Inotiv, Inc. | Bercampur | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -1.0 |
| Purata Bergerak Teknikal | 5.0 |
| Osilator Teknikal | 2.0 |
| Purata | 2.00 |
|
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery and development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, it supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, as well as biotherapeutics and biomedical devices. Through the RMS segment, it offers access to a wide range of small and large research models for basic research and drug discovery and development, as well as specialized models for specific diseases and therapeutic areas. It earns maximum revenue from RMS Segment. |
|
| Sektor | Healthcare |
| Industri | Diagnostics & Research |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 13.48% |
| % Dimiliki oleh Institusi | 13.92% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Kpp Advisory Services Llc | 30 Sep 2024 | 237,718 |
| Fi3 Financial Advisors, Llc | 30 Sep 2024 | 80,710 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 30 Dec 2024 | Pengumuman | Inotiv, Inc. Completes Equity Offering for Net Proceeds of Approximately $3.6 Million |
| 23 Dec 2024 | Pengumuman | Inotiv, Inc. Completes Equity Offering for Net Proceeds of Approximately $24.0 Million |
| 18 Dec 2024 | Pengumuman | Inotiv, Inc. Announces Pricing of Public Offering of 6,000,000 Common Shares |
| 17 Dec 2024 | Pengumuman | Inotiv, Inc. Launches Proposed Public Offering of Common Shares |
| 03 Dec 2024 | Pengumuman | Inotiv Reports Fourth Quarter and Full Year Financial Results for Fiscal 2024 and Provides Business Update |
| 21 Nov 2024 | Pengumuman | Inotiv Ranked Number 138 Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™ |
| 20 Nov 2024 | Pengumuman | Inotiv, Inc. to Report Fiscal 2024 Fourth Quarter and Full Year Results and Host Conference Call on Tuesday, December 3, 2024 |
| 07 Nov 2024 | Pengumuman | Inotiv, Inc. to Participate in Upcoming Jefferies and Craig-Hallum Investor Conferences |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |